Listen
LATUDA (lurasidone), oral antipsychotic
PSYCHIATRY - New medicinal product
Opinions on drugs -
Posted on
Dec 19 2014
Reason for request
Inclusion
No clinical benefit demonstrated in the treatment of schizophrenia in adults compared with existing antipsychotics
- LATUDA has Marketing Authorisation for the treatment of schizophrenia in adults.
- It is an alternative to antipsychotics that are currently available. The clinical data (studies versus placebo and non-inferiority studies) have not demonstrated an advantage compared with the available alternatives.
Clinical Benefit
| Substantial |
The actual benefit of LATUDA is substantial in the treatment of schizophrenia in adults aged 18 years and over. |
Clinical Added Value
| no clinical added value |
LATUDA does not provide an improvement in actual benefit (level V, non-existent) in the treatment of schizophrenia in adults. |
